AXA

AXA today announced the placement of Euro 750 million of Reg S subordinated notes due 2056 (the “Notes”) with institutional investors. This issuance is part of AXA Group’s funding plan, and the proceeds will be used for general corporate purposes, including the refinancing of part of AXA Group’s outstanding debt. The settlement of the Notes is expected to take place on May 29, 2026. The Notes will have a fixed annual interest rate of 4.375% until May 29, 2036, the first call date, following which the interest rate will be a floating rate based on 3-month EURIBOR plus a margin of 240 basis points. The Notes qualify as Tier 2 capital under Solvency II. They will be treated as capital from a regulatory and rating agency perspective within applicable limits. They are expected to be rated A by Standard & Poor’s and A1 (hyb) by Moody’s.

AXA published today the AXA Group 1 Solvency and Financial Condition Report (the “Group SFCR”) for the reporting period ended December 31, 2025, pursuant to Articles 51, 53, 54, 256 and 256a of Directive 2009/138/EC, as amended (the “Directive”) and Articles 290 to 298 and 359 to 364 of Delegated Regulation (EU) 2015/35, as amended (the “Regulation” and, together with the Directive, the “Solvency II Regulations”). The Group SFCR has been prepared in accordance with the Solvency II Regulations governing insurance group reporting and guidance from the European Insurance and Occupational Pensions Authority (EIOPA) and the Autorité de contrôle prudentiel et de résolution (ACPR) and is solely intended to fulfil the requirements thereof. Pursuant to Article 360 of the Regulation, AXA also published today a translation of the summary of the Group SFCR into the official languages of the Member States in which its (re)insurance subsidiaries have their head offices. The Group SFCR and the transl

1Q26 highlights Gross written premiums & other revenues 1 up +6% vs. 1Q25 to Euro 38.0 billion Property & Casualty premiums up +4% to Euro 21.5 billion - Retail premiums up +7% with +4% from price effect and +3% from volumes - Commercial premiums up +3% with equal contributions from price effect and volumes Life & Health premiums up +8% to Euro 16.5 billion - Life premiums up +8% - Health premiums up +8% Life & Health NB CSM up +4% and net flows of Euro +2.7 billion Solvency II ratio 2 at 211% as of March 31, 2026, down -4 points vs. January 1, 2026 (post-grandfathering period) reflecting resilience in a volatile environment Outlook 3 On track to achieve underlying earnings per share growth for 2026 at the upper end of the 6-8% plan target range 4 AXA to present its new strategic plan for 2027-2029 on September 15, 2026

Material Event filed 2026-05-04

Material Event filed 2026-05-04

Following its Annual Shareholders’ Meeting held today in Paris, AXA announces that all resolutions submitted to shareholders were approved with the meeting quorum representing 71.23% of AXA shares. The Shareholders’ Meeting notably approved the consolidated and parent company financial statements for the fiscal year ended December 31, 2025, the payment of a dividend of €2.32 per share (with a payment date on May 13, 2026, and an ex-dividend date on May 11, 2026). The Shareholders’ Meeting overwhelmingly voted in favor of the renewal of the mandate of Thomas Buberl for a four-year term, following which the Board of Directors reappointed him as Chief Executive Officer until the end of his mandate.

Quarterly Report filed 2026-04-30

Material Event filed 2026-04-30